Abbott Receives FDA Approval for Two Three-Month Strengths of Lupron Depot-PED for the Treatment of Central Precocious Puberty

Abbott ABT announced today that the U.S. Food and Drug Administration (FDA) has approved two new strengths for three-month administration of Lupron Depot-PED ® (leuprolide acetate for depot suspension) for the treatment of children with central precocious puberty. CPP is a condition that causes children to enter puberty too soon, resulting in the development and progression of secondary sex characteristics such as breast development in females and genital development in both males and females, and can potentially lead to a diminished adult height. By definition, CPP starts in girls under the age of 8 and boys under the age of 9. Treatment with Lupron Depot-PED helps to arrest pubertal development until a more appropriate time.